New Study on Dual Use of Cigarettes and E-Cigarettes.

Nov.07.2022
New Study on Dual Use of Cigarettes and E-Cigarettes.
A new study published in the Addiction journal found that dual users of e-cigarettes and combustible cigarettes have lower levels of toxic chemicals.

A new study published in the scientific journal Addiction suggests that individuals who use nicotine vapor products or electronic cigarettes while trying to quit smoking have lower levels of toxic chemicals in their bodies. The study analyzed the biomarkers of nearly 1,300 individuals who either smoked traditional cigarettes, used e-cigarettes, or used both in what is known as dual use. The researchers found that compared to traditional cigarette smokers, those who used both products had lower levels of toxic chemicals such as carbon monoxide in their bodies. This contradicts previous beliefs that using e-cigarettes as a smoking cessation method would lead to increased smoking and greater exposure to harmful chemicals from both traditional and electronic cigarettes.


What is "dual use"? Dual use refers to continuing to smoke traditional cigarettes even after starting to use electronic cigarettes. This has become a common practice among those attempting to quit smoking using electronic cigarettes. Many opponents of electronic cigarettes point to the prevalence of dual use as evidence that electronic cigarettes do not help people quit smoking, but rather encourage the development of another harmful habit: vaping.


It cannot be denied that many people are smoking traditional cigarettes and using e-cigarettes simultaneously. Numerous studies in the past two years have repeatedly found that people attempting to quit smoking by using e-cigarettes continue to smoke traditional cigarettes. Additionally, researchers pointed out that the success rate of dual users quitting either traditional cigarettes or e-cigarettes is not higher than those who use nicotine replacement therapy.


Many studies over the past decade have consistently shown that electronic cigarette users frequently engage in dual use, meaning they continue to smoke traditional tobacco cigarettes while using e-cigarettes. This is the case in the United States, United Kingdom, and European Union. For example, American smokers report that e-cigarette use has remained unchanged for three consecutive years, dropping only slightly from 29.8% in 2015 to 27.7% in 2018.


A similar report exists in the United Kingdom as well. A study revealed that the rate of dual use of electronic and traditional cigarettes is higher among teenagers who only use e-cigarettes, despite them being the largest group in the survey. The research also showed that young people who started with traditional cigarettes are more likely to continue to smoke them even after starting to use e-cigarettes.


Many people from different countries and backgrounds, regardless of race and gender, engage in dual use behavior, which seemed to reinforce the belief that e-cigarettes are not helpful for quitting smoking. However, this new study overturns this assumption by stating that dual use is only a transition, not a permanent one.


Is Dual Use of Tobacco and E-cigarettes Risky? Many studies have hinted at the potential danger of using both tobacco and e-cigarettes simultaneously. For instance, one study suggests that the likelihood of developing cardiovascular diseases is higher in individuals who use both products compared to those who only use e-cigarettes but lower than those who only smoke tobacco. However, new evidence from a recent study reveals the opposite.


A new study has examined the levels of carbon monoxide in the breath of cigarette smokers, e-cigarette users and those who use both. The study found that the levels of carbon monoxide in the bodies of those who only use e-cigarettes were lower than those who smoke cigarettes or use both. However, compared to those who only smoke cigarettes, those who use both also had lower levels of carbon monoxide in their bodies.


Another study found that dual users were more likely to quit smoking after a period of time, rather than returning to using only one type or quitting altogether. However, the study also found that, aside from dual use, there were other factors that caused them to stop smoking, unrelated to whether they smoked cigarettes. This study also suggests that those who smoke cigarettes and use electronic cigarettes usually return to only smoking cigarettes.


Can e-cigarettes help you quit smoking? Despite new research, many public health organizations and policymakers are unlikely to change their views on e-cigarettes, at least in America. However, despite the risks, countries like the UK have already adopted e-cigarettes as another tool to help people quit more harmful smoking habits.


Although this new study does offer new evidence in support of the notion that dual smoking is not as harmful as smoking cigarettes alone, it is not definitive proof. Other factors aside from using electronic cigarettes or vaping are relevant in determining whether an individual can successfully quit smoking. However, this study does indicate that going through a transitional period during the process of quitting smoking is harmless.


Statement:


This article is compiled from third-party information and is intended for industry discussion and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of its content. The compilation of this article is intended only for industry exchange and research.


Due to limitations in our translation abilities, the translated article may not express the same meaning as the original. Please refer to the original article for accuracy.


Regarding any domestic, Hong Kong, Macao, Taiwan, or foreign-related statements and positions, 2FIRSTS remains fully aligned with the Chinese government.


The compilation of information is the property of the original media and author, and if there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Philip Morris Korea launched TEREA Limona Pearl in South Korea on August 31, 2026, expanding the TEREA Fresh Blend capsule tobacco stick lineup from four variants to five. Designed for the IQOS ILUMA series, the new stick combines a capsule with what the company calls a Fresh Filter. Philip Morris Korea describes the product as offering an aromatic, refreshing flavor profile with a cooling sensation, with an additional fresh note released when the capsule is crushed. The recommended retail price is KRW 4,800 per pack, with sales through IQOS stores and convenience stores nationwide. No reliable evidence has been found that the same Limona Pearl SKU was previously officially launched in another major IQOS market.
Sep.01
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04